Identification | Back Directory | [Name]
AKT inhibitor 2 | [CAS]
1313881-70-7 | [Synonyms]
ARQ-092 CS-2349 Miransertib ARQ092;ARQ 092 AKT inhibitor 2 ARQ 092 Free Base 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine 2-Pyridinamine, 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl]- | [Molecular Formula]
C27H24N6 | [MDL Number]
MFCD30187510 | [MOL File]
1313881-70-7.mol | [Molecular Weight]
432.52 |
Chemical Properties | Back Directory | [Boiling point ]
700.8±70.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:8.0(Max Conc. mg/mL);18.5(Max Conc. mM) | [form ]
A crystalline solid | [pka]
9.17±0.20(Predicted) | [color ]
Off-white to yellow |
Hazard Information | Back Directory | [Uses]
3-[3-[4-(1-Aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl]-2-pyridinamine is a selective allosteric inhibitor of AKT kinases. | [in vivo]
Miransertib (ARQ-092; Compound 21a) shows good absolute oral bioavailability in rats (5 mg/kg) and monkeys (10 mg/kg) with F values of 62% and 49%, respectively. The half-life is longer in rats compared to monkeys with t1/2 values of 17 h in rats versus 7 h in monkeys. The Cmax is 198 ng/mL and 258 ng/mL and the AUCinf was 5496 h ng/mL and 2960 h ng/mL in rats and monkeys, respectively[1].
Miransertib (ARQ-092; Compound 21a) inhibits tumor growth in a human xenograft mouse model of endometrial adenocarcinoma[1]. | [IC 50]
Akt1: 2.7 nM (IC50); Leishmania; Akt3: 8.1 nM (IC50); Akt2: 14 nM (IC50); Akt1 E17K mutant |
|
Company Name: |
BOC Sciences
|
Tel: |
1-631-485-4226; 16314854226 |
Website: |
https://www.bocsci.com |
|